stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Free cash flow
Grifols, S.A.'s free cash flow for fiscal 2025 was $710.5M, up 18.5% from $599.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $750.4M. Over the past ten years it has ranged from −$403.7M (fiscal 2022) to $1.3B (fiscal 2020); the current reading is higher than 72% of that period. Free cash flow has risen for 3 consecutive fiscal years. Grifols, S.A. ranks 15th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $710.5M | 18.46% |
| FY2024 | $599.8M | — |
| FY2023 | −$88.4M | — |
| FY2022 | −$403.7M | — |
| FY2022 | $0.00 | — |
| FY2021 | $626.9M | (16.48%) |
| FY2021 | $750.6M | (12.16%) |
| FY2020 | $854.5M | (32.10%) |
| FY2020 | $1.3B | 605.17% |
| FY2019 | $178.5M | (72.90%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $270.1M | 109.54% |
| Jun 2026 | $128.9M | 450.69% |
| Mar 2026 | $23.4M | (92.86%) |
| Dec 2025 | $328.0M | 26.41% |
| 31 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR compare | $8.8B |
| NVO Novo Nordisk A/S compare | $6.9B |
| BIIB Biogen Inc. compare | $1.7B |
| GRFS Grifols, S.A. | $750.4M |
| OGN Organon & Co. compare | $572.0M |
| AMRN Amarin Corporation PLC compare | $37.5M |
| NSRX Nasus Pharma Ltd. compare | −$12.1M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement